[ad_1]
Dr. van der Mooren brings three decades of experience in clinical trials
AMSTERDAM, April 12, 2022 /PRNewswire/ — Freya Pharma Solutionsa late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Jan van der Mooren MD, PhD, MSc (picture below) as Chief Medical Officer as per April 2022. Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research since 1990. Prior to his appointment he was Senior Director of the Danone Nutricia Research Center in Utrecht, the Netherlands. Jan will be in the lead of Freya’s steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.
Marcel WijmaExecutive Director at Freya Pharma Solutions said:
“We are very pleased to have Jan join our leadership team as we are on the brink of commencing our phase 3 clinical trial with our promising compound Lybrido, against FSIAD. His depth of experience in clinical trials and knowledge in the field of Gynaecological Endocrinology will be especially valuable during this pivotal time at the company.”
Dr. Van der Mooren brings to Freya three decades of life sciences experience in clinical development and medical affairs in nutrition, epidemiology, obstetrics and gynaecology. Most recently …
Full story available on Benzinga.com
[ad_2]
Source link
